Ampholipad -Systemic Fungal Infections Drug
Ampholipad is a generic of AmBisome, a lipid-encapsulated version of the antifungal drug amphotericin B. Ampholipad successfully demonstrated bioequivalence to AmBisome in all three forms and in both large and small batches, making it the first and only drug to have achieved such a feat. Scaled-up production of Ampholipad™ can surpass a million vials each year, at a capacity capable of meeting increasing global demands.
Most popular related searches
- Bioequivalent to AmBisome®
- Production at over 1 million vials a year
API
Amphotericin B
DDS Platform
Indication
Systemic fungal infection
Development Status
Marketed